PATH (UiPath Inc., NYSE) 05 Feb 2026 close: $12.15 Market Closed, AI positioning signal

We closed the session with UiPath (PATH, NYSE) at $12.15, down -1.46% on 05 Feb 2026. PATH stock traded 37,939,900 shares, above the 30-day average, as investors weighed AI demand versus near-term multiples. UiPath reports EPS of 0.42 and a trailing PE of 28.75, leaving valuation tension against growth. In this piece we review PATH stock fundamentals, technicals, Meyka AI grading, and forecasted price paths for AI-focused investors.

PATH stock: Price action and market context

UiPath closed $12.15 on 05 Feb 2026 after a session range of $11.79–$12.48. Volume hit 37,939,900, above the average volume of 27,562,284, signaling stronger trading interest. The share price sits well below the 50-day average of $15.60 and slightly below the 200-day average of $13.52. We view this as short-term consolidation inside a wider AI adoption trade.

PATH stock: Financials and valuation

UiPath reports trailing EPS of $0.42 and a PE of 28.75, with revenue per share at 2.88. The company has $2.59 cash per share and a current ratio of 2.54, showing a strong liquidity buffer. Price-to-sales is 4.13 and price-to-book is 3.36, which we see as premium for a software infrastructure stock exposed to AI. Management improved margins and delivered year-over-year net income growth of 72.63% in the fiscal update.

PATH stock: AI growth drivers and risks

UiPath’s RPA plus AI integrations remain the core growth engine for enterprise automation adoption. Customers in banking and healthcare drive recurring SaaS revenue and a 25.02% R&D-to-revenue ratio supports product leadership. Key risks include execution on enterprise expansion, receivables days at 116.59, and a premium valuation that could compress if macro sentiment weakens. We treat AI tailwinds as real, but execution must sustain to justify multiples.

PATH stock: Technicals and trading setup

Technicals show neutral momentum: RSI at 48.95 and ADX 18.02, indicating no clear trend. Short-term support sits near the year low $9.38, and resistance clusters around the 50-day average $15.60. Volatility is moderate with ATR 0.96, and on-balance volume at 10,137,314 suggests mixed institutional flows. Traders may prefer range plays while trend indicators remain flat.

Meyka AI rates PATH with a score out of 100

Meyka AI rates PATH with a score out of 100: 76 (B+, Suggestion: BUY). This grade factors in S&P 500 and sector comparisons, industry standing, financial growth, key metrics, forecasts, and analyst consensus. The grade reflects strong balance sheet metrics, improving profitability, and AI market exposure. These grades are informational only and are not financial advice.

Meyka AI’s forecast model projects PATH stock price paths

Meyka AI’s forecast model projects monthly $14.00, quarterly $14.27, and yearly $17.12 targets for PATH stock. Versus the current $12.15, implied upside is 15.23% for one month, 17.45% for one quarter, and 40.93% over one year. Forecasts are model-based projections and not guarantees. We recommend monitoring upcoming earnings on 2026-03-11 and catalysts that could move the stock.

Final Thoughts

Key takeaways for PATH stock: UiPath closed at $12.15 on 05 Feb 2026 with elevated volume and mixed technicals. Financially, the company shows improving profitability and a strong liquidity position, but valuation metrics like PE 28.75 and P/S 4.13 leave limited margin for disappointment. Meyka AI rates PATH 76/100 (B+, BUY) and projects a yearly target of $17.12, an implied upside of 40.93% versus today’s price. We view PATH as a selective AI growth holding for investors who accept execution risk and near-term volatility. Monitor March earnings and adoption indicators to reassess conviction. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.